{"id":"W2242698841","doi":"10.1200/jco.2015.33.7_suppl.487","title":"cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Papillary renal cell carcinomas; Medicine; Internal medicine; Cabozantinib; Oncology; Cohort; Cancer; Renal cell carcinoma; Clear cell renal cell carcinoma; Chromosome 7 (human); Cancer research; Pathology; Chromosome; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00180772,0.001199209,0.00210032,0.0003836082,0.0004480428,0.001133038,0.0008981742,0.001693378,0.003626234],"category_scores_gemma":[0.001175444,0.0004591063,0.001927411,0.0002895791,0.0006003318,0.0008118351,0.0003805604,0.003177117,0.001088119],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001442334,"about_ca_system_score_gemma":0.001304071,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00129865,"about_ca_topic_score_gemma":0.002921702,"domain_scores_codex":[0.999496,0.0001441892,0.00003018065,0.0001133629,0.0001105676,0.0001056812],"domain_scores_gemma":[0.9993091,0.00008455996,0.0001097384,0.00006152244,0.00006378144,0.0003713609],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.425286,0.07270992,0.01367192,0.002161628,0.004570071,0.001678682,0.0008387974,0.01174346,0.1883042,0.0009170263,0.01520606,0.2629121],"study_design_scores_gemma":[0.4133638,0.5018638,0.04068427,0.00008028842,0.001364303,0.003093895,0.0001340007,0.005473436,0.02208549,0.0006034187,0.01114949,0.0001038302],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873195,0.003329071,0.0008066481,0.001079113,0.0001645731,0.001953412,0.002312026,0.0001733897,0.002862278],"genre_scores_gemma":[0.9847017,0.001850341,0.001772423,0.001038604,0.00008031704,0.001243981,0.005434318,0.0000532692,0.003824976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003626234,"threshold_uncertainty_score":0.01213092,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1653189872127203,"score_gpt":0.4756816781265127,"score_spread":0.3103626909137923,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}